TP53 and acute myeloid leukemia: The ICC further subdivides MDS/AML into (i) MDS/AML with mutated TP53, (ii) MDS/AML with myelodysplasia-related gene mutations or cytogenetic abnormalities, and (iii) MDS/AML, NOS (not otherwise specified).